Apollo Endosurgery, Inc. Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ: APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced certain preliminary unaudited financial expectations for the three months ended June 30, 2017, including preliminary revenue and operating loss estimates and expected cash balance.

Preliminary Unaudited Second Quarter 2017 Financial Expectations

  • Total GAAP revenue is estimated to be in the range of $16.9 million to $17.1 million for the three months ended June 30, 2017, compared to total GAAP revenue of $17.3 million in the same period in 2016, representing a decrease of 1% to 2%. Total GAAP revenue included $0.3 million of U.S. Orbera starter kit sales in the quarter ended June 30, 2017, compared to $1.1 million in starter kit sales in the same period in 2016, which was a very active quarter for U.S. physician training for Orbera following the product’s August 2015 FDA approval. After adjusting for sales of U.S. Orbera starter kits, total non-GAAP revenue is estimated to be in the range of $16.6 million to $16.8 million for the three months ended June 30, 2017 compared to $16.2 million in the same period in 2016, representing an increase of 2% to 4%.
  • Total GAAP Endo-Bariatric product sales is estimated to be in the range of $9.4 million to $9.5 million for the three months ended June 30, 2017, compared to $8.4 million in the same period in 2016, representing an increase of 12% to 13%. Total GAAP Endo-Bariatric product sales for the three months ended June 30, 2017 and June 30, 2016 includes U.S. Orbera starter kit sales of $0.3 million and $1.1 million, respectively. Excluding these starter kit sales, total Adjusted Endo-Bariatric product sales increased 25% to 26% over the same period in 2016.
  • Total GAAP surgical product sales is estimated to be in the range of $7.3 million to $7.4 million for the three months ended June 30, 2017, compared to $8.8 million in the same period in 2016, representing a decrease of 16% to 17%.
  • Total GAAP operating loss is estimated to be in the range of $5.5 million to $6.0 million for the three months ended June 30, 2017, compared to $6.3 million in the same period in 2016, including depreciation and amortization expenses of $2.5 million and $2.3 million, respectively.
  • Total cash, cash equivalents and restricted cash is estimated to be $6.2 million as of June 30, 2017.

Non-GAAP Financial Measures

To supplement Apollo’s preliminary financial estimates presented on a GAAP basis, Apollo provides certain non-GAAP financial measures, including Non-GAAP revenue and Adjusted Endo-Bariatric product sales. Non-GAAP revenue and Adjusted Endo-Bariatric product sales are supplemental measures of Apollo’s performance that are not required by, and are not determined in accordance with, GAAP. Non-GAAP revenue is defined as total GAAP revenue excluding one-time U.S. Orbera starter kit sales associated with the U.S. Orbera physician training program. Adjusted Endo-Bariatric product sales is defined as GAAP product sales of Orbera and Overstitch excluding one-time U.S. Orbera starter kit sales associated with the U.S. Orbera physician training program. Apollo believes that the non-GAAP financial measures included herein are helpful in understanding Apollo’s past financial performance and evaluating Apollo’s future results. A reconciliation for each non-GAAP financial measure to its most directly comparable GAAP financial measure follows.

Reconciliation of GAAP to Non-GAAP Financial Expectations:
Three Months Ended
June 30, 2017
(Estimated)
Three Months Ended
June 30, 2016
(Actual)
(in millions)
Total GAAP Revenue $ 16.9 – 17.1 $ 17.3
Orbera starter kits (0.3 ) (1.1 )
Total Non-GAAP Revenue $ 16.6 – 16.8 $ 16.2
Three Months Ended
June 30, 2017
(Estimated)
Three Months Ended
June 30, 2016
(Actual)
(in millions)
Total GAAP Endo-Bariatric product sales $ 9.4 – 9.5 $ 8.4
Orbera starter kits (0.3 ) (1.1 )
Adjusted Endo-Bariatric product sales $ 9.1 – 9.2 $ 7.3
spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles